Skip to main content
Premium Trial:

Request an Annual Quote

Sarah Cannon Cancer Institute Acquires Genospace

NEW YORK (GenomeWeb) – Hospital Corporation of America (HCA) today announced that it will acquire personalized medicine software developer Genospace.

Under the terms of the deal, Genospace will merge with HCA's Sarah Cannon cancer institute as a wholly-owned subsidiary. Financial and other terms of the agreement were not disclosed.

"As genomic information advances, it is crucial that oncologists and researchers have rapid access to an efficient and nimble technology solution for interpreting molecular data and guiding clinical decision making," Sarah Cannon Chief Medical Officer Howard Burris III said in a statement.

Genospace is developing a cloud-based platform that includes applications for data analysis, clinical trial matching, patient and physician portals, and hosting for disease-specific online communities. Sarah Cannon said it will incorporate the genomics data technology into its oncology programs in the US and the UK.

Sarah Cannon expects to complete the deal in the first quarter of fiscal year 2017. Genospace will remain headquartered in Cambridge, Massachusetts.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.